Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.44 |
| ▸ | CA9 | Q16790 | 4/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MITF | O75030 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL781780 | 0.90 | ALDH1A1 (0.52) | CA12CA9CA2ALDH1A1HPGD | |
| SCHEMBL224316 | 0.85 | — | — | |
| SCHEMBL10348297 | 0.84 | ALDH1A1 (0.43) | CA12CA9CA2ALDH1A1HPGD | |
| SCHEMBL5204543 | 0.81 | CA12 (0.44) | CA12CA9CA2ALDH1A1HPGD | |
| SCHEMBL24162327 | 0.80 | LMNA (0.41) | CA12CA9CA2ALDH1A1HPGD | |
| SCHEMBL31457896 | 0.80 | CA12 (0.40) | CA12CA9CA2ALDH1A1HPGD | |
| SCHEMBL10489425 | 0.80 | CA12 (0.48) | CA12CA9CA2ALDH1A1HPGD | |
| SCHEMBL19674066 | 0.79 | MLYCD (0.43) | ALDH1A1HPGDTSHRLMNARAB9A | |
| SCHEMBL12339144 | 0.78 | CA12 (0.46) | CA12CA9CA2ALDH1A1HPGD | |
| SCHEMBL13317119 | 0.78 | ALDH1A1 (0.56) | CA12CA9CA2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092034-A1 | 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME | KULEON LLC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20250340513-A1 | NEUROPLASTOGENS AND NON-HALLUCINOGENIC SEROTONIN 5-HT2A/2C RECEPTOR MODULATORS | KULEON LLC (US) | 2025-11-06 | — | — | US | disclosed |
| US-12441683-B2 | 7-methyl indole analogs and dosage forms containing the same | Kuleon, LLC (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250282722-A1 | 7-METHYL INDOLE ANALOGS AND DOSAGE FORMS CONTAINING THE SAME | KULEON LLC (US) | 2025-09-11 | — | — | US | disclosed |
| US-12344582-B2 | Mixed serotonin 5-HT2A/2C receptor agonists and methods for treating pain and depression | Kuleon, LLC (US) | 2025-07-01 | — | — | US | disclosed |
| US-12275701-B2 | Neuroplastogens and non-hallucinogenic serotonin 5-HT2A receptor modulators | Kuleon, LLC (US) | 2025-04-15 | — | — | US | disclosed |
| US-20250091991-A1 | MIXED SEROTONIN 5-HT2A/2C RECEPTOR AGONISTS AND METHODS FOR TREATING PAIN AND DEPRESSION | Kuleon, LLC (US) | 2025-03-20 | — | — | US | disclosed |
| US-12187678-B2 | Methods of treating psychological disorders through the administration of serotonin 5-HT2C receptor modulators | Kuleon, LLC (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240343690-A1 | Neuroplastogens and Non-Hallucinogenic Serotonin 5-HT2A Receptor Modulators | KULEON LLC (US) | 2024-10-17 | — | — | US | disclosed |
| EP-4384172-A1 | HALLUCINOGENIC AND NON-HALLUCINOGENIC SEROTONIN RECEPTOR AGONISTS AND METHODS OF MAKING AND USING THE SAME | Kuleon LLC (US) | 2024-06-19 | — | — | EP | disclosed |
| US-7939689-B2 | Short-acting sedative hypnotic agents for anesthesia and sedation | THERAVANCE, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-20090253787-A1 | SHORT-ACTING SEDATIVE HYPNOTIC AGENTS FOR ANESTHESIA AND SEDATION | THERAVANCE, INC. (US) | 2009-10-08 | — | — | US | disclosed |
| US-7514425-B2 | Short-acting sedative hypnotic agents for anesthesia and sedation | THERAVANCE, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20060116424-A1 | Short-acting sedative hypnotic agents for anesthesia and sedation | THERAVANCE BIOPHARMA R&D IP, LLC | 2006-06-01 | — | — | US | disclosed |
| US-7015346-B2 | Short-acting sedative hypnotic agents for anesthesia and sedation | THERAVANCE, INC. (US) | 2006-03-21 | — | — | US | disclosed |
| US-20050113364-A1 | Short-acting sedative hypnotic agents for anesthesia and sedation | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-05-26 | — | — | US | disclosed |
| US-6887866-B2 | Short-acting sedative hypnotic agents for anesthesia and sedation | THERAVANCE, INC. (US) | 2005-05-03 | — | — | US | disclosed |
| EP-1509492-A2 | SHORT-ACTING SEDATIVE HYPNOTIC AGENTS FOR ANESTHESIA AND SEDATION | Theravance, Inc. (US) | 2005-03-02 | — | — | EP | disclosed |
| WO-2004037750-A2 | SHORT-ACTING SEDATIVE HYPNOTIC AGENTS FOR ANESTHESIA AND SEDATION | THERAVANCE, INC. (US) | 2004-05-06 | — | — | WO | disclosed |
| US-20030153554-A1 | Short-acting sedative hypnotic agents for anesthesia and sedation | THERAVANCE BIOPHARMA R&D IP, LLC | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092034-A1 | 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME | HTR2C, HTR7, HTR6 | CA12 2458/4885CA9 1661/4885CA2 2151/4885 |
| US-20250282722-A1 | 7-METHYL INDOLE ANALOGS AND DOSAGE FORMS CONTAINING THE SAME | HTR7, HTR2C, HTR1A | CA12 4829/4885CA9 4826/4885CA2 4598/4885 |
| US-20090253787-A1 | SHORT-ACTING SEDATIVE HYPNOTIC AGENTS FOR ANESTHESIA AND SEDATION | GABRA5, GABRA6, GABRA2 | CA12 2258/4885CA9 1524/4885CA2 687/4885 |
| US-12441683-B2 | 7-methyl indole analogs and dosage forms containing the same | HTR7, HTR2C, HTR1A | CA12 4829/4885CA9 4826/4885CA2 4598/4885 |
| US-12275701-B2 | Neuroplastogens and non-hallucinogenic serotonin 5-HT2A receptor modulators | HTR2A, HTR2C, HTR1A | CA12 4277/4885CA9 4869/4885CA2 4215/4885 |
| US-20050113364-A1 | Short-acting sedative hypnotic agents for anesthesia and sedation | GABRA5, GABRA6, GABRA2 | CA12 2258/4885CA9 1524/4885CA2 687/4885 |
| US-12187678-B2 | Methods of treating psychological disorders through the administration of serotonin 5-HT2C receptor modulators | HTR2C, HTR2A, HTR3B | CA12 4452/4885CA9 4870/4885CA2 3748/4885 |
| US-20250340513-A1 | NEUROPLASTOGENS AND NON-HALLUCINOGENIC SEROTONIN 5-HT2A/2C RECEPTOR MODULATORS | HTR2A, HTR2C, HTR3A | CA12 4068/4885CA9 4864/4885CA2 3924/4885 |
| US-20030153554-A1 | Short-acting sedative hypnotic agents for anesthesia and sedation | GABRA5, GABRA6, GABRA2 | CA12 2258/4885CA9 1524/4885CA2 687/4885 |
| US-20060116424-A1 | Short-acting sedative hypnotic agents for anesthesia and sedation | GABRA5, GABRA6, GABRA2 | CA12 2258/4885CA9 1524/4885CA2 687/4885 |
| US-12344582-B2 | Mixed serotonin 5-HT2A/2C receptor agonists and methods for treating pain and depression | HTR2A, HTR2C, HTR3A | CA12 4149/4885CA9 4795/4885CA2 2724/4885 |
| US-20240343690-A1 | Neuroplastogens and Non-Hallucinogenic Serotonin 5-HT2A Receptor Modulators | HTR2A, HTR2C, HTR1A | CA12 4277/4885CA9 4869/4885CA2 4215/4885 |
| US-20250091991-A1 | MIXED SEROTONIN 5-HT2A/2C RECEPTOR AGONISTS AND METHODS FOR TREATING PAIN AND DEPRESSION | HTR2A, HTR2C, HTR3A | CA12 4149/4885CA9 4795/4885CA2 2724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.